Here's Why You Should Consider Buying Regeneron Pharma (REGN)'s Shares
Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 938,500 | $492,712,500 | +70% | 1.01% |
| 2. | D E Shaw D. E. Shaw | 777,469 | $408,171,225 | +35% | 0.29% |
| 3. | Citadel Investment Group Ken Griffin | 680,505 | $357,265,125 | +809% | 0.06% |
| 4. | Millennium Management Israel Englander | 338,826 | $177,883,650 | +100% | 0.09% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 297,691 | $156,287,775 | +5% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $844.61 | 1,000 | $844,610.00 | 12,931 | 2024-11-01 | Filing | |
| $1,059.28 | 2 | $2,118.56 | 17,582 | 2024-10-01 | Filing | |
| $1,057.38 | 2 | $2,114.76 | 17,584 | 2024-10-01 | Filing | |
| $1,056.68 | 3 | $3,170.04 | 17,586 | 2024-10-01 | Filing | |
| $1,054.90 | 3 | $3,164.70 | 17,589 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,424,048 | $4,947,625,200 | 0.08% | |
| 2. | 9,276,085 | $4,869,944,458 | 0.09% | |
| 3. | 4,832,002 | $2,536,801,050 | 0.1% | |
| 4. | 3,939,618 | $2,068,312,374 | 0.14% | |
| 5. | 3,826,283 | $2,008,798,575 | 1.13% |
News See All
Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now.
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc.
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
11 Best GLP-1 and Weight Loss Stocks to Invest in
GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite.
BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds.
11 Most Undervalued Long Term Stocks to Buy According to Hedge Funds
BlackRock sees risk assets in a tug-of-war between strong US corporate earnings, driven by the AI theme, and tariffs that impact growth while increasing inflation.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Call Transcript August 1, 2025Regeneron Pharmaceuticals, Inc. beats earnings expectations.
Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, Inc.